Progeria Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight | Amgen, Sanofi, Novartis, Eiger Biopharmaceuticals, Teva Pharmaceuticals, Schering-Plough, PRG Science & Technology, Boston Scientific Corporati

DelveInsight's "Progeria Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Progeria, historical and forecasted epidemiology as well as the Progeria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Progeria Market Share @ Progeria Market Outlook- https://www.delveinsight.com/sample-request/progeria-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Progeria Market Report
• In January 2025, PRG Science & Technology Co. Ltd announced a study to determine the Optimal Dose and Evaluate the Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients with Hutchinson-Gilford Progeria Syndrome (HGPS).
• According to NORD (n.d.), HGPS and Werner syndrome are rare disorder that appears to affect males and females equally and all races equally. The prevalence of HGPS is approximately 1 in 20 million, so at any given time, approximately 400 children are living with progeria worldwide. It is a rare disorder that affects males and females equally. Werner syndrome's frequency has been estimated at 1-20 per one million individuals in the United States. Although certain associated findings are present beginning during childhood, puberty, and young adulthood, the disorder is most frequently recognized in the third or fourth decades of life.
• Coppedè (2016) reported a birth prevalence of 1 in 8 million HGPS, but considering misdiagnosed or unreported cases, the estimated prevalence is 1 in 4 million births.
• As per the data by Orphanet (n.d.), the prevalence of Werner syndrome among Japanese and Sardinian populations is estimated to be 1/50,000 due to founder mutations. Prevalence in other populations is unknown but may be around 1/200,000.
• Werner syndrome is the most common form of progeria. The first signs of this disorder appear only after puberty, with the full symptoms manifesting in individuals 20-30 years old. A much rarer progeria, Hutchinson-Gilford syndrome, develops earlier: victims die, apparently of old age, typically around age 12. Fortunately, this hereditary disease occurs very infrequently.
• The increase in Progeria Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Progeria Market is anticipated to witness growth at a considerable CAGR.
• The leading Progeria Companies such as Amgen, Sanofi, Novartis, Eiger Biopharmaceuticals, Teva Pharmaceuticals, Schering-Plough, PRG SCience & Technology, Boston Scientific Corporation, and others.
• Promising Progeria Pipeline Therapies such as Progerinin, Lonafarnib, Zoledronic Acid, Pravastatin and others.

Stay ahead in the Progeria Therapeutics Market with DelveInsight's Strategic Report @ Progeria Market Outlook- https://www.delveinsight.com/sample-request/progeria-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr

Progeria Epidemiology Segmentation in the 7MM
The epidemiology section of Progeria offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Progeria Epidemiology trends @ Progeria Prevalence- https://www.delveinsight.com/sample-request/progeria-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr

Marketed Progeria Drugs
• ZOKINVY (lonafarnib): Eiger BioPharmaceuticals
ZOKINVY, developed by Eiger BioPharmaceuticals, is a groundbreaking therapy that targets the underlying cause of progeria by inhibiting the production of the toxic protein progerin. Zokinvy stands as the pioneering and sole treatment designed to address both the cause and symptoms of progeria, which is also referred to as Hutchinson-Gilford Progeria Syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL), in individuals aged 12 months and above. The drug was approved by the US FDA in 2020 and by EMA in 2022.

Progeria Drugs Market Insights
The Progeria market is expected to experience gradual changes, mainly due to the limited availability of emerging therapies in this area. Key market players, including PRG Science & Technology Co., Ltd, Eiger BioPharmaceuticals, and others, have demonstrated a keen interest in this rare condition and are actively pursuing the development of potential treatments.

Emerging Progeria Drugs
• Progerinin: PRG Science & Technology Co., Ltd.
Previous research discovered that inhibiting the binding between progerin and lamin A (using a compound referred to as JH4) could improve the pathological characteristics associated with Hutchinson-Gilford Progeria Syndrome (HGPS). PRG Science & Technology is developing Progerinin (PRG-S-1 and PRG-S-2) for the treatment of progeria, including HGPS and Werner Syndrome, respectively, in Phase II clinical trials.

To learn more about Progeria treatment guidelines, visit @ Progeria Treatment Market Landscape- https://www.delveinsight.com/sample-request/progeria-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr

Progeria Market Outlook
The report's outlook on the Progeria market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Progeria therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Progeria drug and late-stage pipeline therapy.

Progeria Drugs Uptake
The drug chapter of the Progeria report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Progeria.

Major Progeria Companies
Amgen, Sanofi, Novartis, Eiger Biopharmaceuticals, Teva Pharmaceuticals, Schering-Plough, PRG Science & Technology, Boston Scientific Corporation, and others.

Learn more about the FDA-approved drugs for Progeria @ Drugs for Progeria Treatment- https://www.delveinsight.com/sample-request/progeria-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Progeria Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Progeria Companies- Amgen, Sanofi, Novartis, Eiger Biopharmaceuticals, Teva Pharmaceuticals, Schering-Plough, PRG SCience & Technology, Boston Scientific Corporation, and others.
• Progeria Pipeline Therapies- Progerinin, Lonafarnib, Zoledronic Acid, Pravastatin and others.
• Progeria Market Dynamics: Progeria Market Drivers and Barriers
• Progeria Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Progeria Drugs in development @ Progeria Clinical Trials Assessment- https://www.delveinsight.com/sample-request/progeria-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Progeria Executive Summary
3. Progeria Competitive Intelligence Analysis
4. Progeria: Market Overview at a Glance
5. Progeria: Disease Background and Overview
6. Patient Journey
7. Progeria Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Progeria Unmet Needs
10. Key Endpoints of Progeria Treatment
11. Progeria Marketed Products
12. Progeria Emerging Therapies
13. Progeria: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Progeria Market Outlook
16. Access and Reimbursement Overview of Progeria
17. KOL Views
18. Progeria Market Drivers
19. Progeria Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2025

NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Psoriasis Vulgaris Market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Immune Checkpoints Activators Market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Diabetic Wound Market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Overactive Bladder Syndrome Market- https://www.delveinsight.com/report-store/underactive-bladder-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.